Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...

Vertex, Inc. VERX reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance on ...

The 12-month price targets assessed by analysts reveal further insights ... Stay informed and make strategic decisions with our Ratings Table. Vertex Inc is a provider of tax technology and services.

Vertex Pharmaceuticals Inc. (VRTX) has disclosed a new risk, in the Innovation / R&D category. Vertex Pharmaceuticals Inc. faces ...

Analyst Joshua Reilly of Needham maintained a Buy rating on Vertex (VERX – Research Report), boosting the price target to $60.00. Joshua ...

KING OF PRUSSIA, Pa. (AP) — KING OF PRUSSIA, Pa. (AP) — Vertex, Inc. (VERX) on Wednesday reported third-quarter profit of $7.2 million. On a per-share basis, the King Of Prussia, Pennsylvania-based ...

The astonishing rally in U.S. stocks that started at the beginning of 2023 was predominantly driven by the technology sector.

From blue chip dividend stocks to industry-leading growth stocks, there are plenty of bargains in today's market if you know ...

Additionally, VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) had 505 shares sold from the ARKG ETF, valued at $238,314. Lastly, ARK bought 559,162 shares of PACIFIC BIOSCIENCES OF CALIFORNIA INC (NASDAQ ...

BMO Capital lowered the firm’s price target on Dow Inc. (DOW) to $54 from $57 and keeps a Market Perform rating on the shares ...